Xilio Therapeutics Secures $35.8M from Warrant Exercises, Extends Cash Runway into Q2 2027
Summary
Xilio Therapeutics announced the successful exercise of Series B warrants, generating $35.8 million in gross proceeds and extending its cash runway into the second quarter of 2027.
Key Events
-
Series B Warrants Exercised
48,207,815 Series B warrants were exercised by December 31, 2025, generating $35.8 million in total gross proceeds for the company.
-
Cash Runway Extended
The company anticipates its existing cash and the proceeds from the Series B warrant exercises will fund operations into the second quarter of 2027.
-
Future Capital Potential
48,207,815 Series C warrants remain outstanding, with an exercise price of $0.75 per warrant, potentially generating up to an additional $36.2 million by the end of 2026.
-
Shares Outstanding Update
As of January 2, 2026, there were 67,540,930 shares of common stock issued and outstanding.
Analysis
This 8-K filing details a critical capital infusion for Xilio Therapeutics, which is vital for its operations as a life sciences company. The successful exercise of Series B warrants, generating $35.8 million in gross proceeds, provides substantial funding. This capital, combined with existing resources, is projected to fund operations into the second quarter of 2027, significantly reducing near-term liquidity concerns and providing a longer runway for its clinical programs. Additionally, the company highlights the potential for another $36.2 million from outstanding Series C warrants, further bolstering its financial outlook if exercised, though their exercise price of $0.75 is slightly above the current stock price of $0.6996.
At the time of this filing, XLO was trading at $0.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $35.3M. The 52-week trading range was $0.62 to $1.70. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.